[go: up one dir, main page]

MX2016002924A - Inhibidores de cinasa a base de eter arilico. - Google Patents

Inhibidores de cinasa a base de eter arilico.

Info

Publication number
MX2016002924A
MX2016002924A MX2016002924A MX2016002924A MX2016002924A MX 2016002924 A MX2016002924 A MX 2016002924A MX 2016002924 A MX2016002924 A MX 2016002924A MX 2016002924 A MX2016002924 A MX 2016002924A MX 2016002924 A MX2016002924 A MX 2016002924A
Authority
MX
Mexico
Prior art keywords
kinase inhibitors
aryl ether
base kinase
base
compounds
Prior art date
Application number
MX2016002924A
Other languages
English (en)
Inventor
Vivekananda M Vrudhula
Ramkumar Rajamani
John E Macor
Joanne J Bronson
Carolyn Diane Dzierba
Susheel Jethanand Nara
Maheswaran Sivasamban Karatholuvhu
Senliang Pan
Original Assignee
Squibb Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Squibb Bristol Myers Co filed Critical Squibb Bristol Myers Co
Publication of MX2016002924A publication Critical patent/MX2016002924A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención está dirigida generalmente a compuestos que pueden inhibir las composiciones de AAK1 (cinasa 1 asociada al adaptador) que comprenden tales compuestos y a los métodos para inhibir la AAK1.
MX2016002924A 2013-09-11 2013-09-11 Inhibidores de cinasa a base de eter arilico. MX2016002924A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2013/059185 WO2015038112A1 (en) 2013-09-11 2013-09-11 Aryl ether-base kinase inhibitors

Publications (1)

Publication Number Publication Date
MX2016002924A true MX2016002924A (es) 2016-06-06

Family

ID=49253405

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016002924A MX2016002924A (es) 2013-09-11 2013-09-11 Inhibidores de cinasa a base de eter arilico.

Country Status (8)

Country Link
US (1) US20160222021A1 (es)
EP (1) EP3044226B1 (es)
JP (1) JP6243539B2 (es)
CN (1) CN105683196B (es)
CA (1) CA2941192A1 (es)
EA (1) EA029744B1 (es)
MX (1) MX2016002924A (es)
WO (1) WO2015038112A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2958924B1 (en) 2013-02-22 2016-12-28 Bristol-Myers Squibb Company 5h-chromeno[3,4-c]pyridines as inhibitors of adaptor associated kinase 1 (aak1)
US10253027B2 (en) 2013-07-08 2019-04-09 Bristol-Myers Squibb Company Aryl lactam kinase inhibitors
WO2015054358A1 (en) 2013-10-11 2015-04-16 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
CA2937529A1 (en) * 2014-01-29 2015-08-06 Bristol-Myers Squibb Company Aryl lactam kinase inhibitors
EA028942B1 (ru) 2014-04-02 2018-01-31 Бристол-Майерс Сквибб Компани Биарильные ингибиторы киназы
EP3292124B1 (en) * 2015-04-10 2019-05-22 Bristol-Myers Squibb Company 6h-isochromeno[3,4-c]pyridines and benzo[c][1,7]naphthyridin-6-(5h)-ones as adaptor associated kinase 1 (aak1) inhibitors
WO2017059085A1 (en) 2015-10-01 2017-04-06 Bristol-Myers Squibb Company Biaryl kinase inhibitors
WO2017059080A1 (en) 2015-10-01 2017-04-06 Bristol-Myers Squibb Company Biaryl kinase inhibitors
JP2025538197A (ja) * 2022-11-10 2025-11-26 シーザン ハイスーク ファーマシューティカル カンパニー リミテッド Ａａｋ１阻害剤を含有する医薬組成物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3896137A (en) * 1974-03-11 1975-07-22 Smithkline Corp 8-alkyl and alkenyl-10-hydroxy-5h(1)benzopyranopyridine derivatives and uses thereof
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
AU2515992A (en) 1991-08-20 1993-03-16 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
JP2003510349A (ja) * 1999-10-07 2003-03-18 ノヴァ−ニューロン インコーポレーテッド 線条体機能に必要な遺伝子、その使用、およびそれを調節するための化合物
AU2004263871B2 (en) 2003-08-06 2011-07-14 Senomyx, Inc. T1R hetero-oligomeric taste receptors, cell lines that express said receptors, and taste compounds
WO2006016548A1 (ja) 2004-08-09 2006-02-16 Eisai R & D Management Co., Ltd. ヘテロ環化合物を含有する新規な抗マラリア剤
US8357637B2 (en) * 2007-05-29 2013-01-22 Cornell University Molecules involved in regulation of osteoblast activity and osteoclast activity, and methods of use thereof
WO2013134336A2 (en) * 2012-03-09 2013-09-12 Lexicon Pharmaceuticals, Inc. Inhibition of adaptor associated kinase 1 for the treatment of pain
US8703953B2 (en) * 2012-03-09 2014-04-22 Bristol-Myers Squibb Company Aryl ether-base kinase inhibitors

Also Published As

Publication number Publication date
CN105683196B (zh) 2018-12-21
WO2015038112A1 (en) 2015-03-19
EA201690244A1 (ru) 2016-07-29
EP3044226B1 (en) 2017-09-06
EP3044226A1 (en) 2016-07-20
EA029744B1 (ru) 2018-05-31
CA2941192A1 (en) 2015-03-19
JP6243539B2 (ja) 2017-12-06
JP2016535759A (ja) 2016-11-17
US20160222021A1 (en) 2016-08-04
CN105683196A (zh) 2016-06-15

Similar Documents

Publication Publication Date Title
MX2016012829A (es) Inhibidores de biaril cinasa.
MX2016002924A (es) Inhibidores de cinasa a base de eter arilico.
PH12018501151A1 (en) Tank-binding kinase inhibitor compounds
MX2015000980A (es) Inhibidores de aril lactama cinasa.
MX2016009352A (es) Inhibidores de quinasa a base de quinolina.
MX2015008999A (es) Inhibidores mk2 y usos de los mismos.
MX2016015862A (es) Compuestos inhibidores de la cinasa de union a tank.
MX2016003843A (es) Inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos.
WO2013134336A3 (en) Inhibition of adaptor associated kinase 1 for the treatment of pain
PH12016500676B1 (en) Pyrimidine fgfr4 inhibitors
EA201491647A1 (ru) Основанные на арилэфирах ингибиторы киназ
MX2015015421A (es) Inhibidores de acetil-coa carboxilasa (acc) y usos de los mismos.
TW201613886A (en) 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones
PH12015502141A1 (en) Substituted xanthines and methods of use thereof
MX2015015417A (es) Inhibidores de acetil-coa carboxilasa (acc) y usos de los mismos.
MX2017003930A (es) Derivados de aminotriazina utiles como compuestos inhibidores de la cinasa de union a tank.
PH12017500293A1 (en) Boronic acid derivatives
MX2017004037A (es) Derivados de acido boronico.
PH12016500347A1 (en) Triazolopyridine compounds, compositions and methods of use thereof
MX2016009355A (es) Inhibidores de aril lactama cinasa.
MX2017004043A (es) Derivados de acido boronico.
MX370336B (es) Derivados de acido boronico.
PH12016501071A1 (en) Serine/threonine kinase inhibitors
TW201612165A (en) Preparation method for aromatic heterocyclic compound used as selective jak3 and/or jak1 kinase inhibitor and application of aromatic heterocyclic compound
MA39824A (fr) Composés azole amido-substitués